<DOC>
	<DOC>NCT00690287</DOC>
	<brief_summary>The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study safety and tolerability in patients with type 2 diabetes.</brief_summary>
	<brief_title>A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Treated with diet or metformin. Stable glycemic control indicated by no changed treatment within 3 months Diabetes Mellitus diagnosis &lt;5 years Clinically significant illness or clinically relevant trauma, as judged by the investigator, within two weeks before the first administration of the investigational product Clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Type 2 diabetes</keyword>
</DOC>